Loss of ADAR1 in tumours overcomes resistance to immune checkpoint blockade.

Nature64.80
Volume: 565, Issue: 7737, Pages: 43 - 48
Published: Jan 1, 2019
Abstract
Most patients with cancer either do not respond to immune checkpoint blockade or develop resistance to it, often because of acquired mutations that impair antigen presentation. Here we show that loss of function of the RNA-editing enzyme ADAR1 in tumour cells profoundly sensitizes tumours to immunotherapy and overcomes resistance to checkpoint blockade. In the absence of ADAR1, A-to-I editing of interferon-inducible RNA species is reduced,...
Paper Details
Title
Loss of ADAR1 in tumours overcomes resistance to immune checkpoint blockade.
Published Date
Jan 1, 2019
Journal
Volume
565
Issue
7737
Pages
43 - 48
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.